Streetbeat News

Equity Actions

SIDU

Sidus Space reported a FY23 EPS of $(23.11), an improvement from $(74.80) YoY, with revenue decreasing to $5.96M from $7.29M YoY. The company saw a 26% decrease in cost of revenue and a 14% increase in gross profit, driven by higher margin satellite business. SG&A expenses rose due to legal costs and acquisition expenses, leading to a net loss of $14.3M. Cash decreased to $1.2M, with a subsequent increase in funds through warrant exercises and offerings. Liabilities increased across accounts payable, asset-based loan liability, and notes payable.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 12:15 pm

DIS

Egan-Jones and ISS recommend Disney shareholders vote 'FOR' Nelson Peltz and Jay Rasulo for the board, citing the need for change due to Disney's lack of a long-term succession plan, a disconnected board, an outdated business model, a desire to maintain the status quo, and mediocre financial performance. Shareholders are urged to vote 'WITHHOLD' on Maria Elena Lagomasino and Michael B.G. Froman before the April 3, 2024, annual meeting.

Portfolio Pulse from Happy Mohamed

March 27, 2024 | 12:08 pm

STRO

Sutro Biopharma (NASDAQ:STRO) received mixed analyst ratings with a shift towards a more cautious outlook over the past three months. The average 12-month price target was adjusted to $11.75, marking a 7.26% decrease from the previous target. Analysts from Oppenheimer, Wedbush, JMP Securities, and HC Wainwright & Co. provided updates, with some maintaining and others lowering their price targets. The company's financial performance shows a significant revenue decline and challenges in ROE and ROA, despite efficient cost management indicated by its net margin.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 12:01 pm

KRC

Kilroy Realty (NYSE:KRC) received mixed ratings from 4 analysts, with a shift towards a more indifferent stance in the last 30 days. The average 12-month price target is now $40.5, down from $45.50, indicating a 10.99% decrease. The company, a REIT owning 17 million square feet of office space, has seen a -5.39% revenue decline and boasts strong financial metrics like a 17.47% net margin and a 0.87% ROE. Despite challenges, its financial health remains robust with a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 12:01 pm

EVAX

Evaxion Biotech reported a cash and cash equivalents balance of $5.6M for 2023 and successfully raised an additional $12.7M in capital. This financial boost is expected to extend the company's cash runway into April 2025, providing stability and supporting its ongoing projects and research endeavors.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:36 am

BWMN

Bowman Consulting Group's shares are trading lower following the announcement of a $45 million public offering of common stock priced at $34 per share.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:21 am

ROIV

Roivant Sciences' stock is trading higher following the announcement that it will be included in the S&P MidCap 400 index.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:16 am

GMDA

Gamida Cell announced the start of a restructuring process with the support of Highbridge Capital Management. This strategic move aims to streamline operations and strengthen the company's financial position. The involvement of Highbridge Capital, a well-known investment firm, suggests a significant commitment to turning around Gamida Cell's fortunes.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:09 am

IBIO

iBio, Inc. (IBIO) has announced a collaboration with AstralBio, Inc. to develop novel antibodies for treating obesity and cardiometabolic diseases. This follows iBio's recent $15 million private placement financing aimed at supporting new partnerships like the one with AstralBio.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:06 am

PLUR

Pluri Inc. has announced a 1-for-8 reverse share split, effective at the market open on April 1. This action will consolidate every eight shares of Pluri Inc. into one share, potentially affecting the stock's liquidity and market perception.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:05 am